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Percutaneous Left Atrial Appendage Transcatheter Occlusion to
Prevent Stroke in High-Risk Patients With Atrial Fibrillation
Early Clinical Experience
Horst Sievert, MD; Michael D. Lesh, MD; Thomas Trepels; Heyder Omran, MD; Antonio Bartorelli, MD;
Paola Della Bella, MD; Toshiko Nakai, MD; Mark Reisman, MD; Carlo DiMario, MD;
Peter Block, MD; Paul Kramer, MD; Dirk Fleschenberg; Ulrike Krumsdorf; Detlef Scherer, MD
Background—Thromboembolism due to atrial fibrillation (AF) is a frequent cause of stroke. More than 90% of thrombi
in AF form in the left atrial appendage (LAA). Obliteration of the appendage may prevent embolic complications.
Methods and Results—We evaluated the feasibility and safety of implanting a novel device for percutaneous left atrial
appendage transcatheter occlusion (PLAATO). LAA occlusion using the PLAATO system was attempted in 15 patients
with chronic AF at high risk for stroke, who are poor candidates for long-term warfarin therapy. The implant consists
of a self-expanding nitinol cage covered with a polymeric membrane (ePTFE). The LAA was successfully occluded in
15/15 patients (100%). Angiography and transesophageal echocardiography (TEE) during the procedure showed that the
device was well-seated in all patients and that there was no evidence of perforation, device embolization, or interference
with surrounding structures. In 1 patient, the first procedure was complicated by a hemopericardium, which occurred
during LAA access. A second attempt 30 days later was successful with no untoward sequela. No other complications
occurred. At 1-month follow-up, chest fluoroscopy and TEE revealed continued stable implant position with smooth
atrial-facing surface and no evidence of thrombus.
Conclusions—Thus, transcatheter closure of the LAA is feasible in humans. This novel implant technology may be
appropriate for patients with AF who are not suitable candidates for anticoagulation therapy. Further trials are needed
to show the long-term safety and its efficacy in reducing stroke. (Circulation. 2002;105:1887-1889.)
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Patients with atrial fibrillation (AF) are at high risk ofthromboembolic stroke. Anticoagulation treatment with
warfarin is effective, but it is difficult to manage in clinical
practice. Several echocardiographic, surgical, and postmor-
tem studies have demonstrated that, in nonrheumatic AF,
90% to 100% of the thrombi form in the left atrial appendage
(LAA).1–4 Occluding the LAA may therefore prevent throm-
boembolism in these patients.
A new device has been developed that allows percutaneous
left atrial appendage transcatheter occlusion (PLAATO) via
transseptal catheterization. Studies in dogs demonstrated the
ability of the device to seal the LAA.5 We report our initial
experience in humans.
Methods
Patient Selection
Patients with nonrheumatic AF and contraindications to long-term
warfarin therapy, who were identified as high risk for thromboem-
bolism based on the presence of congestive heart failure, diabetes
mellitus, hypertension, history of transient ischemic attack/stroke, or
spontaneous echo contrast in the LAA on transesophageal echocar-
diography (TEE), were recruited into the study.
PLAATO Device and Procedure
The PLAATO system (Appriva Medical), consists of an implant and
a delivery catheter. The implant (Figure 1) is a self-expanding nitinol
cage (range of diameters from 15 to 32 mm) covered with an
occlusive expanded polytetrafluoroethylene (ePTFE) membrane,
which is laminated directly to the frame structure so that the
perimeter has intimate contact with the inner wall of the appendage.
The purpose of the membrane is both to occlude the orifice of the left
atrial appendage and to allow tissue incorporation into the device.
Small anchors along the struts and passing through the occlusive
membrane assist with device anchoring and encourage healing
response. The device is delivered through a custom 14Fr transseptal
sheath curved to point at the LAA.
All procedures were performed under TEE guidance. After trans-
septal access, angiography was performed to assess the size and
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shape of the appendage (Figure 2a). An initial device was chosen that
had a diameter 20% to 40% larger than the diameter of the LAA
ostium. Patients were given heparin (after transseptal puncture) in
order to keep activated clotting time (ACT) 250 seconds. The
delivery catheter and transseptal sheath were withdrawn, revealing
the implant, which was allowed to expand, filling the appendage.
Radiocontrast was injected both distal (through a special lumen in
the device; Figure 2b) and proximal (ie, in the left atrium [LA]) to
assess for leaks and positioning. If sealing was not adequate, the
device was collapsed, repositioned, and re-expanded, or completely
removed while transseptal access was maintained and replaced with
a device of different diameter. Until final release, devices were
completely retrievable. Final seal was evaluated via contrast fluo-
roscopy in the LA once the device had been completely released
(Figure 2c).
Follow-Up Evaluation
All patients were placed on aspirin, 300 mg per day indefinitely, and
clopidogrel, 75 mg per day for 6 months after the procedure. Patients
were assessed with sequential chest fluoroscopy, transthoracic echo-
cardiography, and clinical examination. TEE with color Doppler was
performed 1 month after the procedure.
Results
LAA occlusion was attempted in 15 patients (59 to 78, 695
years) with chronic AF. The contraindications to warfarin
included cerebral hemorrhage in 1, gastrointestinal bleeding
in 9, unstable INR in 2, and severe chronic liver disease in 1
patient. Three patients had a thromboembolic event while on
warfarin treatment. Risk factors for stroke6 included older age
75 years in 3, hypertension in 12, diabetes mellitus in 3, and
a history of stroke in 2. Abnormalities of the atrial septum and
LAA clots were excluded by TEE just before the procedure in
all. No patient had significant mitral or aortic valve disease.
TEE showed spontaneous echo contrast in the LAA or LA in
4, and LAA emptying velocity 20cm/s in 3.
The LAA was successfully occluded in 15/15 patients. The
mean orifice diameter of the LAA was 20.14.3 mm and the
median size of the final implanted device was 26 mm (range
18 to 32 mm). Mean procedure time from initial groin
puncture to removal of all sheaths was 92.743.3 minutes.
In 1 patient, the initial procedure was complicated by
hemopericardium associated with LAA access before device
implantation and diagnosed with intraprocedure TEE. The
procedure was halted and pericardiocentesis performed with-
out sequelae. The appendage was successfully occluded 4
weeks later.
The implant was removed and exchanged for a new size in
patient Nos. 3, 4, 5, and 8 with no problems. The series of
device changes in these 4 patients was 26 to 29 to 18 mm, 29
to 32 mm, 29 to 26 to 23 to 32 mm, and 32 to 32 mm. In 11/15
patients, the first device selected was implanted without need
for exchange. At 1-month follow-up in all patients, chest
X-ray and TEE revealed stable implant position, no evidence
of migration, erosion, or encroachment on surrounding struc-
tures, and smooth healing on the LA-facing surface with no
thrombi and no remaining atrial shunt after transseptal punc-
ture. There have been no late complications or embolic events
during follow-up.
Discussion
AF is responsible for 20% of all strokes.7–9 Several large trials
have demonstrated the efficacy of anticoagulation with war-
farin in reducing the annual stroke rate in patients with AF.
However, warfarin can be a difficult medication to administer
or to take. Its use is associated with an increased risk of major
(1% to 2%/year) and minor (5% to 10%/year) hemorrhagic
complications.10 The effectiveness of warfarin is affected by
a number of drug and dietary interactions, which can be
difficult to manage. Frequent blood tests to monitor INR are
required, at some cost and patient inconvenience.
Despite clear guidelines, warfarin is not used or used
improperly on a large scale.11–14 In perhaps the largest and
most influential survey, Stafford and Singer14,15 found that in
only about a third of outpatients was anticoagulation used.
There is an extensive literature supporting the notion that
the LAA is the source of cardioemboli in over 90% of patients
with AF, at least in those without rheumatic valve disease.1 It
is logical therefore to hypothesize that closing or obliterating
the LAA would be an effective way to prevent most cardio-
emboli in patients with AF. Techniques for surgical obliter-
Figure 1. The implant is constructed of a nitinol frame and an
implant occlusion membrane consisting of a laminated ePTFE.
Small anchors along the frame and passing through the occlu-
sive membrane assist with device anchoring.
Figure 2. Left atrial angiogram: (a) after
transseptal puncture and LAA cannula-
tion, contrast injection outlines LAA from
which an ostial diameter can be mea-
sured; (b) contrast injection via a lumen
through the implant reveals hang up of
dye behind the sealing surface, indicat-
ing proper position and occlusion; (c)
after device release, contrast injection in
the LA establishes complete seal.
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ation have been described.16,17 Nonetheless, surgical or tho-
racoscopic LAA closure, other than as an adjunctive
procedure as recommended by ACC guidelines18 in patients
undergoing mitral valve surgery, has not been enthusiastically
accepted because of its invasive nature.
PLAATO provides for a less invasive, percutaneous ap-
proach to closing the LAA. Previous animal studies of the
device with follow-up of up to 1 year have demonstrated
occlusion of the LAA with complete healing, absence of
erosions, new thrombus formation on the device, or interfer-
ence with atrial function.19
In this initial cohort of 15 patients, occlusion of the LAA
was successful in all, as proven by LA angiography. There
have been no complications associated with the device, either
acutely during the implantation procedure or during follow-
up. The only complication during the study was hemoperi-
cardium in the first patient attempted, which was not device-
related, resulted from LAA access, and should be easily
avoided with increased experience. The procedure was suc-
cessful in a second attempt in this patient.
All patients have done well in follow-up. One theoretical
concern is the development of new thrombi on the implant.
However, the use of ePTFE on the implant surface results in
particularly benign healing.20 Histological examination in
dogs undergoing PLAATO reveal partial endothelialization at
1 month, which is complete by 2 to 3 months. In our patients,
TEE at 1 month has shown the surface to be completely
smooth and free of mobile thrombi.
Conclusion
This initial study supports the concept that implantation of a
mechanical device to occlude the LAA can be done safely and
with relative ease. Further studies are needed before
PLAATO can be recommended for the large number of
patients with AF at risk for stroke. These studies will need to
confirm reduction in stroke incidence and longer term safety.
The attraction of the procedure, however, resides in its
directly addressing the mechanism of stroke in AF and its
operational simplicity. It may become a valuable alternative
for those patients with chronic nonrheumatic AF in whom
standard anticoagulation therapy is contraindicated or poorly
tolerated.
Note Added in Proof
Since acceptance of this manuscript, 16 additional patients
have been treated. In 1 patient, a hemopericardium occurred
during a successful implantation without sequelae. No other
complication occurred.
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